Literature DB >> 20162297

Thrombophilic risk factors in the pathogenesis of non-arteritic anterior ischemic optic neuropathy patients.

Taxiarchis Felekis1, Nikolaos I Kolaitis, Georgios Kitsos, Georgios Vartholomatos, Konstantinos L Bourantas, Ioannis Asproudis.   

Abstract

BACKGROUND: Non-arteritic anterior ischemic optic neuropathy (N-AION) is caused by acute ischemic infarction of the optic nerve head, supplied by the posterior ciliary arteries. Thrombophilia is the tendency/predisposition to vascular thromboses of arteries and veins, and the existence of thrombophilic risk factors leads to blood hypercoagulability and potentially increased risk for thromboses.
OBJECTIVES: To investigate whether there is an association between N-AION and a wide spectrum of thrombophilic risk factors. PATIENTS AND METHODS: Seventy-seven consecutive cases of confirmed N-AION and 60 age- and sex-matched consecutive controls constituted the study group. Fibrinogen levels, deficiency of proteins C, S, ATIII, lupus anticoagulant, activated protein C resistance, factor V Leiden, factor V H1299R, factor II G20210A, MTHFR C677T, MTHFR A1298C, GPIIIa A1/A2, and ACE I/D polymorphisms were analysed.
RESULTS: Statistical analysis of the plasma proteins in our study demonstrated that the only significant difference was the one concerning protein S levels. In particular, the mean value for N-AION patients was 78.8% +/- 21.2, and for the control group the mean value was 88% +/- 21.2 (p = 0.013). Despite the above-mentioned result, there was not any statistical difference between the two subgroups regarding actual protein S deficiency, as 9/77 (11.7%) patients and 4/60 (6.7%) controls had protein S levels below 60% (p = 0.32). In our study sample, homozygosity for MTHFR C677T polymorphism in the study group as a whole, and the presence of at least one A2 allele of GPIIIa in the subgroup of male patients as compared to healthy male controls, proved to be the most significant thrombophilic risk factors, with odds ratios of 16.78 (95% C.I 0.96-294.42, p = 0.054) and 4.6 (95% C.I 1.52-13.88, p = 0.007) respectively.
CONCLUSION: Screening for these polymorphisms would probably constitute a valuable procedure in N-AION patients, as they may have an important contribution to the pathogenesis of the disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20162297     DOI: 10.1007/s00417-010-1308-y

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  37 in total

1.  Erectile dysfunction drugs and nonarteritic anterior ischemic optic neuropathy.

Authors:  Andrew G Lee; Nancy J Newman
Journal:  Am J Ophthalmol       Date:  2005-10       Impact factor: 5.258

2.  Characteristics of patients with nonarteritic anterior ischemic optic neuropathy eligible for the Ischemic Optic Neuropathy Decompression Trial.

Authors: 
Journal:  Arch Ophthalmol       Date:  1996-11

3.  Anterior ischemic optic neuropathy associated with viagra.

Authors:  A V Cunningham; K H Smith
Journal:  J Neuroophthalmol       Date:  2001-03       Impact factor: 3.042

4.  Optic disc structure in anterior ischemic optic neuropathy.

Authors:  R W Beck; P J Savino; M X Repka; N J Schatz; R C Sergott
Journal:  Ophthalmology       Date:  1984-11       Impact factor: 12.079

5.  Nonarteritic anterior ischemic optic neuropathy in patients with sleep apnea while being treated with continuous positive airway pressure.

Authors:  Raed Behbehani; Michaela K Mathews; Robert C Sergott; Peter J Savino
Journal:  Am J Ophthalmol       Date:  2005-03       Impact factor: 5.258

Review 6.  Molecular genetics and gene expression in atherosclerosis.

Authors:  P A Doevendans; W Jukema; W Spiering; J C Defesche; J J Kastelein
Journal:  Int J Cardiol       Date:  2001 Sep-Oct       Impact factor: 4.164

Review 7.  Inherited thrombophilia in arterial disease: a selective review.

Authors:  Philippe de Moerloose; Françoise Boehlen
Journal:  Semin Hematol       Date:  2007-04       Impact factor: 3.851

8.  Nonarteritic ischemic optic neuropathy developing soon after use of sildenafil (viagra): a report of seven new cases.

Authors:  Howard D Pomeranz; Abdhish R Bhavsar
Journal:  J Neuroophthalmol       Date:  2005-03       Impact factor: 3.042

9.  Bilateral anterior ischemic optic neuropathy after liposuction.

Authors:  Rod Foroozan; Joseph Varon
Journal:  J Neuroophthalmol       Date:  2004-09       Impact factor: 3.042

10.  Anterior ischemic optic neuropathy due to abdominal hemorrhage after laparotomy for uterine myoma.

Authors:  Bernhard M Stoffelns
Journal:  Arch Gynecol Obstet       Date:  2009-05-10       Impact factor: 2.344

View more
  5 in total

1.  Association Study of MTHFR Polymorphisms with Nonarteritic Anterior Ischemic Optic Neuropathy in a Spanish Population.

Authors:  Beatriz Fernández-Vega; Lydia Álvarez; Montserrat García; Enol Artime; Marta Diñeiro Soto; Javier Nicieza; José A Vega; Héctor González-Iglesias
Journal:  Biomed Hub       Date:  2020-01-21

2.  Genetic polymorphisms of apolipoprotein E in nonarteritic anterior ischemic optic neuropathy.

Authors:  Yuyu Chou; Zixi Sun; Ye Wang; Yuhan Wang; Jin Ma; Dianxi Zhang; Yong Zhong
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-03-08       Impact factor: 3.535

3.  A case of nonarteritic anterior ischemic optic neuropathy of a male with family history of the disease after receiving sildenafil.

Authors:  T Felekis; I Asproudis; K Katsanos; Ev Tsianos
Journal:  Clin Ophthalmol       Date:  2011-10-07

4.  A case of recurrent transient monocular visual loss after receiving sildenafil.

Authors:  Asaad Ghanem Ghanem
Journal:  Case Rep Ophthalmol Med       Date:  2011-12-22

Review 5.  The association between diabetes mellitus and nonarteritic anterior ischemic optic neuropathy: a systematic review and meta-analysis.

Authors:  Ting Chen; Delu Song; Guangliang Shan; Ke Wang; Yiwei Wang; Jin Ma; Yong Zhong
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.